Histogen is a regenerative medicine company with multiple product candidates in clinical development addressing underserved, multibillion dollar global markets. The Company’s patented technology focuses on replacing and regenerating tissues in the body with materials that have been shown to support human cell growth and differentiation. Histogen’s technology has potential therapeutic benefit in multiple treatment settings to include skin care, orthopedic indications such as cartilage formation and spinal disc repair, wound healing and dermal fillers.
Histogen has raised $38M in equity, the majority of which has been used to develop and optimize its proprietary manufacturing process, submit patents in a number of countries, and refine and advance its products. The Company intends to build on previous clinical experience through completion of U.S. clinical trials of its hair growth, joint cartilage and dermal filler products in 2020 and 2021.
On September 9, 2019 Chairman and CEO Richard Pascoe presented a corporate overview and clinical update at the H.C. Wainwright Global Investment Conference in New York. A webcast of the presentation can be viewed here: http://wsw.com/webcast/hcw5/his/
For more information about investment opportunities please contact:
Director of Corporate Communications